An observational study in Dietary Exposure, Diabetes Mellitus, Type 2 and Cardiovascular Diseases, sponsored by German Federal Institute for Risk Assessment. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2025-02-14.
Sponsored by German Federal Institute for Risk Assessment · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 756 studies in Diabetes Mellitus, Type 2 with a site in Germany — 46 open to participants now, 67 under way, 23 of them phase 3. Diabetes Mellitus, Type 2 · Germany.
Among the 756 studies in Diabetes Mellitus, Type 2 with a site in Germany, this one is the 16th largest by planned enrollment of the 66 observational ones that give a count, is one of 20 that started in 2024, is one of 66 observational ones, reaches primary completion later than 22 of the 66 other live ones, and was the 695th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →46 of the 756 studies in Diabetes Mellitus, Type 2 with a site in Germany are open now. Recruiting first, the newest first:
German Institute of Human Nutrition · Sites in Germany
Ages 40–75 · Healthy volunteers
Novo Nordisk A/S · Sites in Germany
Ages 25–69 · Healthy volunteers
Eli Lilly and Company · Sites in Germany, United States, Argentina and 8 more countries
Ages 18+
German Institute of Human Nutrition · Sites in Germany
Ages 40–75 · Healthy volunteers
Ascletis Pharma (China) Co., Limited · Sites in Germany, United States, Czechia and 3 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 69 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
756 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 147 · Phase 2 104 · Phase 3 285 · Phase 4 79
First in 1998; this study’s year is marked. 20 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6,000 is above the median of 300 across 1,749 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 218 across the 688 interventional studies, 1,552 across the 66 observational. Of the 655 that completed or were terminated, 263 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
597 of 756 have an industry lead sponsor. The 10 most frequent:
German Federal Institute for Risk Assessment is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
German Federal Institute for Risk Assessment has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
18 of the studies in Diabetes Mellitus, Type 2 with a site in Germany that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
Add all 18 to your calendar (.ics) → With an account.
Among the 756 studies in Diabetes Mellitus, Type 2 with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Cohort on Plant-based Diets (COPLANT) study is a multi-centre cohort study that starts baseline recruitment from 2024 to 2027 with approximately 6,000 participants in Germany and Austria. The COPLANT study focuses on vegan (no animal products), vegetarian (no meat and fish, but dairy products and eggs), pescetarian (no meat, but fish) and omnivorous (mixed diet including all possible animal products) diets. The aim of the COPLANT study is to gain new insights on health benefits and risks as well as social, ecological and economic effects of different plant-based diets in comparison to a mixed diet. In addition to a detailed dietary survey using an app adapted to the needs of this study, the baseline examination includes measurements of body composition, bone health, cardiovascular risk factors, diabetes risk, contaminants and lifestyle. For the basic laboratory program, fasting blood, 24-hour urine collection and a stool sample are taken from all study participants. Furthermore, specific aspects of dietary behavior, physical activity and other lifestyle factors are collected via questionnaires. Follow-up studies are planned at intervals of 5, 10 and 20 years after the baseline visit.
The multicenter Cohort on Plant-based diets (COPLANT) study, aims to investigate the health benefits as well as short-term and long-term risks of different plant-based diets (vegan: no animal products, vegetarian: no meat and fish, but dairy products and eggs, pescetarian: no meat, but fish) compared to a mixed diet among 6,000 participants aged 18 to 69 years across German speaking countries. Currently the impact of different diets not only on health effects, but also on social, ecological and economic factors is becoming increasingly evident in areas of social justice, climate change and animal welfare. For this reason, a sustainability analysis (social, ecological and economic effects) together with findings on health effects will be included in the COPLANT study. As plant-based diets, especially vegan diets, are associated with specific risks and benefits for certain population groups such as pregnant women, breastfeeding mothers and children, COPLANT will also establish appropriate research structures for these groups and include them in the study.
The detailed consumption survey of all study participants is one of the main pillars of the planned study. Of particular importance is the dietary assessment of novel vegan and vegetarian foods, thus an app adapted to the needs of this study was developed. The characterisation of external and internal intakes of nutrients and contaminants within a particular diet will be examined. Large epidemiological projects currently underway in Germany, such as the NAKO Health Study, are unable to answer these questions. In order to prospectively investigate links between diet and the later occurrence of common diseases such as type 2 diabetes, cardiovascular diseases and cancer, the study participants should be followed up for at least 20 years if third-party funding is successfully acquired.
The study is to be conducted in study centers at the Federal Institute for Risk Assessment (BfR), Berlin, the Max Rubner-Institut (MRI) in Karlsruhe, the Rheinische Friedrich-Wilhelms University in Bonn, the Friedrich Schiller University Jena, the Research Institute for Plant-Based Nutrition in Giessen, in cooperation with the Justus Liebig University Giessen and at the universities of Heidelberg, Regensburg and Vienna. Furthermore, the basic examination includes measurements of body composition, bone health, cardiovascular risk factors, diabetes risk, contaminants and lifestyle. Specific aspects of dietary behavior, physical activity and other lifestyle factors will be assessed using questionnaires. For the basic laboratory program, fasting blood, 24-hour urine collection and a stool sample are taken from all study participants.
Participants will be recruited for the baseline study from 2024 to 2027. Follow-up visits are planned at intervals of 5, 10 and 20 years.
Vegans - no consumption of animal products (less than one exception per month)
Vegetarians
Pescetarians
Omnivores/ mixed diet - group of non-exposed persons or control group
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
vegan diet: no products of animal origin
vegetarian diet: no meat and fish, but dairy products and eggs
pescetarian diet: no meat, but fish
mixed diet: plant-based foods and animal-based foods
Incidence of diabetes type 2
Incidence of diabetes type 2
Time frame: 5, 10, 20 years
Incidence of cardiovascular diseases
Incidence of cardiovascular diseases
Time frame: 10, 20 years
Incidence of cancer
Incidence of cancer
Time frame: 10, 20 years
Vitamin B12
Vitamin B12 (pmol/l)
Time frame: Baseline
Holo-transcobalamine
Holo-transcobalamine (pmol/l),
Time frame: Baseline
Homocysteine
Homocysteine (µmol/l)
Time frame: Baseline
Methylmalonic acid
Methylmalonic acid (µg/l)
Time frame: Baseline
Vitamin B1 status
Vitamin B1 (nmol/l)
Time frame: Baseline
Vitamin B2 status
Vitamin B2 (µg/l)
Time frame: Baseline
Vitamin B6 status
Vitamin B6 (nmol/l)
Time frame: Baseline
Vitamin C status
Vitamin C (mg/l)
Time frame: Baseline
Vitamin D status
Vitamin D (nmol/l)
Time frame: Baseline
Vitamin E status
Vitamin E (µmol/l)
Time frame: Baseline
Iron
Iron (µmol/l)
Time frame: Baseline
Ferritin
Ferritin (µg/l)
Time frame: Baseline
Transferrin
Transferrin (mg/dl)
Time frame: Baseline
Zinc status
Zinc (µg/l)
Time frame: Baseline
Selenium status
Selenium (µg/l)
Time frame: Baseline
Iodine status
Iodine (µg/l)
Time frame: Baseline
Blood pressure
Systolic blood pressure (mm Hg), diastolic blood pressure (mm Hg)
Time frame: Baseline
Blood lipids
Total cholesterol, LDL, HDL, triacylglycerides (mmol/l)
Time frame: Baseline
Fasting insulin
Fasting insulin (mU/l)
Time frame: Baseline
Fasting glucose
Fasting glucose (mmol/l)
Time frame: Baseline
Glycated hemoglobin (HbA1c)
HbA1c (%)
Time frame: Baseline
C-peptide
C-peptide (ng/ml)
Time frame: Baseline
Osteocalcin
Osteocalcin (ng/ml)
Time frame: Baseline
Ostase
Ostase (µg/l)
Time frame: Baseline
Parathormone
Parathormone (ng/l)
Time frame: Baseline
N-terminal propeptide of type I procollagen (PINP)
PINP (ng/ml)
Time frame: Baseline
C-terminal telopeptide of type I collagen (CTX)
CTX (ng/ml)
Time frame: Baseline
Creatinine
Creatinine (mmol/24h)
Time frame: Baseline
Uric acid
Uric acid (mg/24h)
Time frame: Baseline
Cytstatin C
Cytstatin C (mg/l)
Time frame: Baseline
Thyroid stimulating hormone (TSH)
TSH (mU/l)
Time frame: Baseline
Free triiodothyronine (fT3)
fT3 (pmol/l)
Time frame: Baseline
Free thyroxine (fT4)
fT4 (pmol/l)
Time frame: Baseline
Body fat
Body fat (kg)
Time frame: Baseline
Skeletal muscle mass
Skeletal muscle mass (kg)
Time frame: Baseline
Total Body Water
Total Body Water (l)
Time frame: Baseline
Energy intake
Calories per day
Time frame: Baseline
Nutrient intake
Milligramm per day
Time frame: Baseline
Intake of dietary supplements
Frequencies per day
Time frame: Baseline
Intake of medication
Frequencies per day
Time frame: Baseline
Heavy metals
Arsenic, lead, cadmium (µg/l)
Time frame: Baseline
Halogenated, polycyclic aromatic hydrocarbons (dioxins)
Dioxins (ng/g lipid)
Time frame: Baseline
Mycotoxins
Mycotoxins (ng/ml)
Time frame: Baseline
Per- and polyfluoroalkyl substances (PFAS)
PFAS (ng/ml)
Time frame: Baseline
Microbiome
16S rRNA sequencing
Time frame: Baseline
Plan to share: Undecided — In accordance with the informed consent of the COPLANT participants, pseudonymised study data could be provided to external researchers upon request for cooperation or data-use purposes. In this case, a cooperation or data use agreement must be concluded in advance. The use of COPLANT study data is therefore only possible with a detailed prior justification of its scientific purpose and after agreement of the steering commitee of the COPLANT study.
Started Apr 2024 (actual). Primary completion is estimated for Mar 2027, 35 months after the start.
Of 436 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's planned 35 months is close to that.
Counting every sponsor, half of 606 studies reached it within 32 months; a quarter within 17 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
German Federal Institute for Risk Assessment